Home Newsfeeds Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3

Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3

Raymond James analyst Steven Seedhouse maintains NexImmune (NASDAQ:NEXI) with a Outperform and lowers the price target from $12 to $3.

byBenzinga Newsdesk

August 16, 2022

1 minute read

Raymond James analyst Steven Seedhouse maintains NexImmune (NASDAQ:NEXI) with a Outperform and lowers the price target from $12 to $3.

Designer Brands Q1: Earnings Miss, Lowered Guidance, Progress On Strategic Plans & More

By Shivani Kumaresan

June 8, 8:50 AM

Designer Brands Inc (NYSE:DBI) reported a first-quarter FY23 sales decline of 10.7% year-on-year to $742.08 million, missing the analyst consensus estimate…

DBI

Mizuho Initiates Coverage On Glaukos with Neutral Rating, Announces Price Target of $48

By Benzinga Newsdesk

December 22, 7:59 AM

Mizuho analyst Anthony Petrone initiates coverage on Glaukos (NYSE:GKOS) with a Neutral rating and announces Price Target of $48.

GKOS

Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday

By Lisa Levin

October 27, 2:39 AM

Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate Cancer Foundation Scientific Retreat.

$APE

InMed Pharmaceuticals Stock Trading Higher On Q3 Sales Growth Of 234%, Here Is What You Need To Know

By Vuk Zdinjak

May 16, 9:21 AM

InMed Pharmaceuticals Inc. (NASDAQ: INM) released its financial results for the third quarter of the fiscal year 2023 which ended March 31, 2023, revealing sales of $1 million, an increase of 234% compared to $309,585 in Q3 2022.

INM

Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3

Related Posts

Designer Brands Q1: Earnings Miss, Lowered Guidance, Progress On Strategic Plans & More

Mizuho Initiates Coverage On Glaukos with Neutral Rating, Announces Price Target of $48

Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday

InMed Pharmaceuticals Stock Trading Higher On Q3 Sales Growth Of 234%, Here Is What You Need To Know